PP 1是一种新型的高效、选择性Src家族酪氨酸激酶抑制剂，PP 1有效抑制Lck（IC50=5nM）和Fyn（IC50=6nM）的磷酸化来阻断T细胞受体信号通路。
Cas No.:172889-26-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
PP 1 is a novel, potent, and selective Src family tyrosine kinase inhibitor. PP 1 effectively inhibits the phosphorylation of Lck (IC50=5nM) and Fyn (IC50= 6nM) to block T-cell receptor signaling pathways. PP 1 can be used in research related to cancers (such as small cell lung cancer and leukemia) as well as T-cell immune signal transduction[1-4].
In vitro, pretreatment of NMuMG/E9 mouse mammary epithelial cells with PP 1 (10μM) for 30min, followed by stimulation with TGF-β1 (1-5ng/mL) for 1-2 days. PP 1 significantly inhibited the occurrence of epithelial-mesenchymal transition (EMT), while preventing alterations in cell morphology, focal adhesion formation, and the activation of Smad2/3[5]. Pretreatment of human coronary artery smooth muscle cells (HCASMCs) and Swiss 3T3 cells with PP 1 (0.1–10μM) for 15min–4h, followed by stimulation with PDGF-BB (10–15ng/mL) for 4–20h. PP 1 significantly inhibited cell migration and proliferation, while reducing the tyrosine phosphorylation level of PDGFβ receptors[6].
In vivo, a single intraperitoneal injection of PP 1 (1.5mg/kg) was administered to treat the transient middle cerebral artery occlusion (tMCAO) mouse model. PP 1 significantly rescued the FUNDC1-mediated neuronal mitophagy dysfunction caused by I/R injury[7]. Daily intraperitoneal injection of PP 1 (2mg/kg) was administered to the unilateral ureteral obstruction (UUO)-induced renal fibrosis mouse model for 3-14 days. PP 1 significantly reduced the deposition of extracellular matrix and inhibited the activation of renal interstitial fibroblasts, thereby ameliorating the development of renal fibrosis[8].
References:
[1] Zan L, Zhang X, Xi Y, et al. Src regulates angiogenic factors and vascular permeability after focal cerebral ischemia-reperfusion. Neuroscience. 2014 Mar 14;262:118-28.
[2] Warmuth M, Simon N, Mitina O, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood. 2003 Jan 15;101(2):664-72.
[3] Karni R, Mizrachi S, Reiss-Sklan E, et al. The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett. 2003 Feb 27;537(1-3):47-52.
[4] Kantibekovna SL, Wang S, Kang H, et al. Selective antitumor and apoptosis‑inducing effects of the Src inhibitor PP1 in human tongue squamous cell carcinoma cells. Int J Oncol. 2026 May;68(5):64.
[5] Maeda M, Shintani Y, Wheelock MJ, et al. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II. J Biol Chem. 2006 Jan 6;281(1):59-68.
[6] Waltenberger J, Uecker A, Kroll J, et al. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circ Res. 1999 Jul 9;85(1):12-22.
[7] Tang T, Hu LB, Ding C, et al. Src inhibition rescues FUNDC1-mediated neuronal mitophagy in ischaemic stroke. Stroke Vasc Neurol. 2024 Aug 27;9(4):367-379.
[8] Yan Y, Ma L, Zhou X, et al. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Kidney Int. 2016 Jan;89(1):68-81.
PP 1是一种新型的高效、选择性Src家族酪氨酸激酶抑制剂，PP 1有效抑制Lck（IC50=5nM）和Fyn（IC50=6nM）的磷酸化来阻断T细胞受体信号通路。PP 1可用于癌症（如小细胞肺癌、白血病）以及T细胞免疫信号传导的相关研究[1-4]。
在体外，PP 1（10μM）预处理NMuMG/E9小鼠乳腺上皮细胞30min，随后以TGF-β1（1-5ng/ml）刺激1-2天，显著抑制上皮间质转化（EMT）的发生，同时阻止细胞形态改变、黏着斑形成及Smad2/3的激活[5]。PP 1（0.1–10μM）预处理人冠状动脉平滑肌细胞（HCASMCs）及Swiss 3T3细胞15min–4h，随后以PDGF-BB（10–15ng/mL）刺激4–20h，显著抑制细胞的迁移与增殖，同时降低PDGFβ受体的酪氨酸磷酸化水平[6]。
在体内，PP 1（1.5mg/kg；单次）腹腔注射于处理短暂性大脑中动脉闭塞（tMCAO）小鼠模型。PP 1显著挽救了由I/R损伤引起的FUNDC1介导的神经元线粒体自噬功能障碍[7]。PP 1（2mg/kg；每日一次）腹腔注射于单侧输尿管梗阻（UUO）诱导的肾纤维化小鼠模型3-14天。PP 1显著减少了细胞外基质的沉积，抑制了肾间质成纤维细胞的激活，从而减轻了肾纤维化的发生发展[8]。
| Cell experiment [1]: | |
Cell lines | NMuMG/E9 cells (mouse mammary epithelial cell line) |
Preparation Method | NMuMG/E9 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 4.5g/L glucose, and 10μg/mL insulin. NMuMG/E9 cells were pretreated with PP 1 (10μM) for 30 minutes, followed by stimulation with TGF-β1 (1-5ng/mL) for up to 2 days. |
Reaction Conditions | 10μM; 30min pretreatment + TGF-β1 (1-5ng/mL) stimulation for up to 2 days |
Applications | PP 1 significantly prevented TGF-β1-mediated epithelial to mesenchymal transition (EMT) in NMuMG/E9 cells. PP 1 effectively inhibited TGF-β1-induced dissolution of cell-cell junctions and formation of stress fibers. Additionally, PP 1 suppressed the TGF-β1-induced expression of mesenchymal markers (such as N-cadherin and fibronectin) and the reduction of the epithelial marker ZO-1. PP 1 blocked the TGF-β1-induced transcriptional upregulation of N-cadherin, Snail, and SIP1, and inhibited the activation (tyrosine phosphorylation) of Src and its downstream substrates (including FAK, paxillin, and p120 catenin). |
| Animal experiment [2]: | |
Animal models | Mice (subjected to unilateral ureteral obstruction - UUO) |
Preparation Method | Mice were administered PP 1 (2mg/kg) via daily intraperitoneal injection for 7 or 14 days. Sham-operated and UUO vehicle-treated mice were used as controls. Mice were sacrificed at specified time points (days 3, 7, and 14) for tissue collection and analysis. |
Dosage form | 2mg/kg; i.p.; daily injection for 3-14 days |
Applications | PP 1 administration significantly reduced the deposition of extracellular matrix (ECM) proteins, as evidenced by Masson trichrome staining. PP 1 significantly inhibited the expression of fibronectin, collagen I, and α-smooth muscle actin (α-SMA), thereby attenuating UUO-induced renal fibrosis and activation of renal interstitial fibroblasts. PP 1 reduced the number of renal epithelial cells arrested at the G2/M phase of the cell cycle. |
References: | |
| Cas No. | 172889-26-8 | SDF | |
| 别名 | 蛋白磷酸酯酶-1(抗原),AGL 1872; EI 275 | ||
| 化学名 | 1-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-4-amine | ||
| Canonical SMILES | CC1=CC=C(C=C1)C2=NN(C3=C2C(=NC=N3)N)C(C)(C)C | ||
| 分子式 | C16H19N5 | 分子量 | 281.36 |
| 溶解度 | ≥ 7.03mg/mL in DMSO, ≥ 20.6 mg/mL in EtOH with ultrasonic | 储存条件 | Desiccate at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5542 mL | 17.7708 mL | 35.5417 mL |
| 5 mM | 710.8 μL | 3.5542 mL | 7.1083 mL |
| 10 mM | 355.4 μL | 1.7771 mL | 3.5542 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet